ALB and hepatocellular carcinoma: The C-reactive protein–albumin–lymphocyte (CALLY) index was independently proposed by Müller et al. and Iida et al. in 2021 as a novel immune-nutritional prognostic tool in hepatocellular carcinoma and highlighting the growing validity and clinical application of composite biomarkers combining systemic inflammation (CRP), immune competence (lymphocytes) and nutritional status (albumin) in oncology [12,13].